EXEL - EXELIXIS, INC.

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 21.9

Open

$ 22.38

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 21.74 - $ 22.46

52 Week Range

$ 18.52 - $ 24.34

Volume

2,475,481

Average Volume

Market Cap

6.69B

Beta (5Y Monthly)

$ 0.68

PE Ratio (TTM)

$ 32.63

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	04-30-2024	03-29-2024	10-Q
2	02-06-2024	12-29-2023	10-K
3	11-01-2023	09-29-2023	10-Q
4	08-01-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-07-2023	12-30-2022	10-K
7	11-01-2022	09-30-2022	10-Q
8	08-09-2022	07-01-2022	10-Q
9	05-10-2022	04-01-2022	10-Q
10	02-18-2022	12-31-2021	10-K
11	11-02-2021	10-01-2021	10-Q
12	08-05-2021	07-02-2021	10-Q
13	05-06-2021	04-02-2021	10-Q
14	02-11-2021	01-01-2021	10-K
15	11-05-2020	10-02-2020	10-Q
16	08-06-2020	07-03-2020	10-Q
17	05-05-2020	04-03-2020	10-Q
18	02-25-2020	01-03-2020	10-K
19	10-30-2019	09-27-2019	10-Q
20	07-31-2019	06-28-2019	10-Q
21	05-01-2019	03-29-2019	10-Q
22	02-22-2019	12-28-2018	10-K
23	11-01-2018	09-28-2018	10-Q
24	08-01-2018	06-29-2018	10-Q
25	05-02-2018	03-30-2018	10-Q
26	02-26-2018	12-29-2017	10-K
27	11-01-2017	09-29-2017	10-Q
28	08-02-2017	06-30-2017	10-Q
29	05-01-2017	03-31-2017	10-Q
30	02-27-2017	12-30-2016	10-K
31	11-03-2016	09-30-2016	10-Q
32	08-03-2016	07-01-2016	10-Q
33	05-04-2016	04-01-2016	10-Q
34	02-29-2016	01-01-2016	10-K
35	11-10-2015	10-02-2015	10-Q
36	08-11-2015	07-03-2015	10-Q
37	04-30-2015	04-03-2015	10-Q
38	03-02-2015	12-31-2014	10-K
39	11-04-2014	09-26-2014	10-Q
40	07-31-2014	06-27-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Exel...
05/03/2024 20:03:17

HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $28 price target.

The Analyst Verdict: Exelixis In The Eyes ...
05/01/2024 18:01:09

TD Cowen Maintains Buy on Exelixis, Raises...
05/01/2024 17:51:44

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $25 to $27.

Exelixis Maintains FY24 Financial Guidance...
04/30/2024 20:59:09

Exelixis Q1 2024 Adj EPS $0.17 Misses $0.2...
04/30/2024 20:19:37

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.24 by 2...

Barclays Downgrades Exelixis to Equal-Weig...
04/11/2024 12:55:26

Barclays analyst Peter Lawson downgrades Exelixis (NASDAQ:EXEL) from Overweight to Equal-Weight and maintains the price targ...

What Analysts Are Saying About Exelixis Stock
04/10/2024 17:00:35

JMP Securities Reiterates Market Outperfor...
04/10/2024 15:08:56

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:EXEL) with a Market Outperform and maintains $27 price ta...

around-4m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying

Around $4M Bet On This Healthcare Stock? C...
02/23/2024 13:25:02

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

RBC Capital Maintains Outperform on Exelix...
02/07/2024 17:21:09

RBC Capital analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Outperform and raises the price target from $26 to...

Recap: Exelixis Q4 Earnings
02/06/2024 21:10:47

Exelixis Q4 Adj EPS $0.33 Beats $0.22 Esti...
02/06/2024 21:06:43

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.22 by 50 ...

Earnings Scheduled For February 6, 2024
02/06/2024 10:42:06

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of ...

Earnings Preview For Exelixis
02/05/2024 19:01:05

Stifel Maintains Hold on Exelixis, Raises ...
02/02/2024 19:29:18

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $23 to $25.

Breaking Down Exelixis: 7 Analysts Share T...
01/30/2024 13:00:52

Barclays Maintains Overweight on Exelixis,...
01/30/2024 10:37:21

Barclays analyst Peter Lawson maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $24 to $25.

Exelixis Announces Detailed Results Of Pha...
01/25/2024 13:05:34

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metast...

bristol-myers-exelixis-reveal-4-year-follow-up-results-from-cancer-treatment-study

Bristol Myers, Exelixis Reveal 4-Year Foll...
01/23/2024 16:11:15

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Bristol-Myers Squibb Announced Opdivo In C...
01/22/2024 22:02:07

Bristol Myers Squibb (NYSE:BMY) and Exelixis, Inc. (NASDAQ:EXEL) today announced four-year follow-up results from the CheckMate...